Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Delayed OTC Markets Other stock markets 14:46:19 17/07/2024 BST			5-day change	1st Jan Change
7 ^USD	-16.37%		-21.79%	+366.67%

05:11pm	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
07-12	European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	MT

Silence Therapeutics plc Appoints Dr. Marie Wikstrom Lindholm to its Board of Directors

January 19, 2022 at 03:37 pm

Silence Therapeutics plc announced that Dr. Marie Wikstrom Lindholm, Senior Vice President, Molecular Design and member of the Silence Executive Leadership Team, has been elected to serve for two years at the Board of Directors of the Oligonucleotide Therapeutics Society (OTS).

Latest news about Silence Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	04:11pm	MT
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	07-12	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	07-08	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	07-02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	06-28	MT
Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating	06-28	MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating	06-28	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	06-27	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-27	MT
Silence Therapeutics Says Divesiran Shows Sustained Hematocrit Reduction in Blood Cancer Study	06-27	MT
Transcript : Silence Therapeutics plc - Special Call	06-27
Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	06-27	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	06-26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	06-21	MT
Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)	06-20	CI
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	06-17	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	06-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	05-30	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	05-28	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	05-22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	05-21	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	05-20	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
Silence Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI

Chart Silence Therapeutics plc

Duration

Period

More charts

Company Profile

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is focused on discovering and developing molecules incorporating short-interfering ribonucleic acid (siRNA) to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body's natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target disease-associated genes in the liver. Its wholly owned product candidates include SLN360, for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein (a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).

Sector

Calendar

11/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company